Research News
Gael Chetelat, PhD, University of Caen-Normandy, France, was honored on Oct. 21, 2022, by Women’s Health Access Matters for her BrightFocus-funded project, “Sex Differences in Risk Profiles Across the Alzheimer’s Disease Continuum.”
A recent article coauthored by BrightFocus Vice President, Scientific Affairs Diane Bovenkamp, PhD, proposes a new way to narrow racial and ethnic disparities in Alzheimer’s research through the development of standardized electronic health records.
New BrightFocus-funded research explores how a protein called tau, critical to Alzheimer’s, turns from normal to a diseased state. This discovery presents a new target to potentially prevent or treat Alzheimer's disease.
Eye-brain research is revealing that the APOE4 mutation has a much different impact in glaucoma than in Alzheimer’s, a discovery that may lead to a new glaucoma treatment.
Press release on a new Alzheimer’s drug which shows promising results to slow disease progression.
A recent study focused attention on whether Alzheimer’s disease can spread from one human to another. The risk remains small as long as standard precautions are followed during surgery and other procedures.
BrightFocus Foundation, a nonprofit and premier source of research funding to defeat Alzheimer’s, macular degeneration, and glaucoma, today was acknowledged as the catalyst behind a major advance in drug development for Alzheimer’s disease.